恆生科技指數僅吐0.9% 美團(03690.HK)逆市續漲近3%再破頂
雖然納指屢創紀錄高,但升幅已連日跑輸藍籌指數。本港恆生科技指數隨大市下跌,現造7,478,僅跌0.9%,跌幅遠少於恆指(曾急挫461點或1.8%,現跌1.5%)。主要受惠憧憬「染藍」恆生科技成份股佔比排三位的美團-W(03690.HK)逆市再破頂支撐,該股四連漲,今早升破周二盤中所創上市高位221.6元,最229.2元,現造224.6元,續升2.8%,成交1,389萬股,涉資31.14億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.